Skip to content
Peptigraph home
Shop Peptides50% off*

Does retatrutide make you tired?

Fatigue was recorded in the phase 2 obesity trial: 3 of 70 placebo participants and 6 of 62 in the arm that stepped up to the top dose reported it. These are small counts and cannot settle the question.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Fatigue was recorded in the phase 2 obesity trial: 3 of 70 placebo participants and 6 of 62 in the arm that stepped up to the top dose reported it. These are small counts and cannot settle the question.[1]

Group EG000 in the phase 2 obesity registry record is the placebo arm.[1]

Group EG006 in the phase 2 obesity registry record is the arm stepped up from 2 mg to 12 mg.[1]

What the second phase 2 trial shows

In the phase 2 trial in type 2 diabetes, nobody on placebo reported fatigue (0 of 45), against 3 of 46 in the top-dose step-up arm.[2]

Group EG007 in the phase 2 diabetes registry record is the arm stepped up from 2 mg to 12 mg.[2]

The phase 2 obesity abstract names gastrointestinal events as the most common adverse events and does not list fatigue among its headline findings.[3]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  2. 2A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  3. 3Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026

Found an error? Report a correction.